GI oncologist focusing on cholangiocarcinoma and neuroendocrine tumors @BIDMChealth @DanaFarber & @HarvardMed. Views are my own. #GIOncology #Cholangiocarcinoma
Boston,MA
Joined January 2010
- Tweets47
- Following287
- Followers159
- Likes153
Pinned Tweet
Just in from @NEJM - Our case report on the use of anti-insulin receptor antibodies as a novel strategy to tackle refractory hypoglycemia and malignant insulinoma! Immensely grateful to my mentors ME Patti and Ahmed Rattani and the ICU & endocrine team @BIDMChealth as well as the patient and their family for their unwavering trust and courage. 🌟 🎉
Read the full story at 🔗 nejm.org/doi/full/10.1056/NE…
#GIoncology
@OncoAlert – at Boston, MA
🔬Ivonescimab now represent a promising emerging therapeutic option - exciting progress for cholangiocarcinoma and biliary tract cancer patients @curecc
HARMONI-GI1 at the @myESMO #ESMO26 #Presidential of CisGem + #ivonescimab vs durvalumab in #firstline #BiliaryMalignancies
✅OS HR 0.75, mOS 12.1vs14.9
✅PFS HR 0.61, mPFS 6.8vs8.4
✅ORR 53.8vs32.5
🌐China only
BUT
😊This is a positive trial
🥳VEGF is back
#ESMOAmbassadors
Alm Soravis Osataphan, MD retweeted
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO… @curecc @MDAndersonnews
Alm Soravis Osataphan, MD retweeted
A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer
#ESMO26 #ESMOAmbassadors
👉 ORR: 18 vs 5.3%
👉 mPFS: 4.7 vs 2.6 mo
👉 mOS: 8.9 vs 9.4 mo
🧐Active drug, but no OS benefit in 2nd line, could be explored in 1L
@myESMO @ASCO
Alm Soravis Osataphan, MD retweeted
ACTICCA-1 trial: Adj. GemCis vs standard of care after curative intent resection of BTC
#ESMO26 #ESMOAmbassadors
👉 DFS at 2yrs: 52 vs 44%
👉mDFS: 23.3 vs 20.6
👉 mOS: 58 vs 48 mo
👉expected toxicity for the doublet
🧐 Trend for OS benefit, not an option for all, but may be considered as option for selected pts
@myESMO @ASCO
Alm Soravis Osataphan, MD retweeted
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
smmttx.com/news/press-releas…
Alm Soravis Osataphan, MD retweeted
A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
Alm Soravis Osataphan, MD retweeted
Last, but not least, @FIGHT302 presented at @ASCO #ASCO26
Pemigatinib vs CisGem for #FGFR2 fusion +ve #CCA in the #FirstLine setting
😓Early interruption (slow accrual) - limited power
🙂Trend - better PFS
😊Significantly increased ORR
👉Supports use of iFGFR in CCA
Alm Soravis Osataphan, MD retweeted
We're just getting started. Deconstruction is underway, and the newly installed wrap is a powerful glimpse of what’s ahead. It’s exciting to see this progress and take another step toward bringing our vision for the future of cancer care to life.
Alm Soravis Osataphan, MD retweeted
We’re seeing exciting progress on the @danafarber BIDMC Collaboration! A wrap has gone up on the site of Dana-Farber’s Future Cancer Hospital that reads, "We're not just raising a building. We're raising the standard of cancer care for everyone."
Alm Soravis Osataphan, MD retweeted
Honored to receive the 🏆 Top Poster Presentation Award at the #ASCO26 Medical Student & Resident Research Forum!
Grateful to my mentors and co-authors! @rushadpatell @alm_o @LaurenOLoughli3 @ASCOTECAG @ASCO @NazliDizman
#Melanoma #HemeOnc #MedTwitter #Oncology
So grateful for an evening with this thoughtful, dedicated and deeply compassionate group of oncologists. Proud to be a part of @BIDMChealth @BIDMC_CancerCtr @DanaFarber @harvardmed community #ASCO2026 💚
@DeepaRangachari @BrunoBockorny @NetanaMarkovitz @grace_ferri @ChanmiLee @brian_russell39 @LaurenOLoughli3 @VinayGiriMD @JRusheen
Phenomenal moment for pancreatic cancer.
Hopefully cholangiocarcinoma and biliary tract cancers are next in the RAS-targeted therapy era.🙏
Congratulations to @RevMedicines, #BrianWolpin @EileenMOReilly and all co-investigators!
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Exploring Chicago with the best crew 🙌🏻 🏙️@BIDMC_HOFellows @DeepaRangachari @brian_russell39 @LaurenOLoughli3 @grace_ferri @NetanaMarkovitz
#ASCO2026
Alm Soravis Osataphan, MD retweeted
🟨Rilvegostomig + Gem-Cis in 1L of advanced BTC
#ASCO26
✅mOS: 16.8 mo
⏰Looking forward to results of phase III Artemide studies
#cancer #oncology #MedX #biliary #cholangiocarcinoma @curecc @PrecisionBTCnet @OncoAlert @AstraZeneca
Alm Soravis Osataphan, MD retweeted
Congratulations to our chief fellow @LaurenOLoughli3 on her oral abstract on professional development in hematology/oncology fellowships! @BIDMC_CancerCtr #asco2026
Alm Soravis Osataphan, MD retweeted
Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events. Full phase 2–3 ZSAB-neoGOLP trial results: nejm.org/doi/full/10.1056/NE…
ALT Original Article | MAR 5, 2026 Neoadjuvant GOLP in Resectable High- Risk Intrahepatic Cholangiocarcinoma (ZSAB-neoGOLP) Figure 2A. Event-free Survival.
Alm Soravis Osataphan, MD retweeted
Excited, happy and proud to share our @Nature publication on neoadjuvant ICB in pMMR colon cancer; #NICHE! We provide validation of previous clinical results, plus extensive and comprehensive analyses of Overdue tweetorial below❗️ nature.com/articles/s41586-0…
A great evening with the BIDMC GI Oncology team celebrating the holidays - grateful to work with such thoughtful and supportive colleagues. Bittersweet as we also send ML Peters off to the next chapter. You’ll be missed, but glad you’re still close by. @BrunoBockorny @pdwhooley @JessZerilloMD @MLBTPeters @BIDMC_CancerCtr
